NO973103L - Fremgangsmåte for inhibering av veksthormoneffekter - Google Patents
Fremgangsmåte for inhibering av veksthormoneffekterInfo
- Publication number
- NO973103L NO973103L NO973103A NO973103A NO973103L NO 973103 L NO973103 L NO 973103L NO 973103 A NO973103 A NO 973103A NO 973103 A NO973103 A NO 973103A NO 973103 L NO973103 L NO 973103L
- Authority
- NO
- Norway
- Prior art keywords
- growth hormone
- inhibiting growth
- hormone effects
- effects
- hexamethylenimino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Fremgangsmåte for inhibering av veksthormoneffekter Fremgangsmåte for inhibering av effekter av veksthormon omfattende administrasjon til et menneske som har behov for dette av en effektiv mengde av en forbindelse av formel 0) ^;^>Ss^^OCH2CH2-r2 hvor r1 og r3 uavhengig er hydrogen, -CH3, 0 0 -C-(Ci-C6 alkyl) eller -C-Ar, hvor Ar er eventuelt substituert fenyl; r2 er valgt fra gruppen bestående av pyrrolidin, heksametylenimino og piperidino; eller et farmasøytisk akseptabelt salt eller solvat derav.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/372,753 US5494929A (en) | 1995-01-12 | 1995-01-12 | Methods of inhibiting growth hormone effects |
PCT/US1995/016809 WO1996021441A1 (en) | 1995-01-12 | 1995-12-22 | Methods of inhibiting growth hormone effects |
Publications (2)
Publication Number | Publication Date |
---|---|
NO973103L true NO973103L (no) | 1997-07-03 |
NO973103D0 NO973103D0 (no) | 1997-07-03 |
Family
ID=23469503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO973103A NO973103D0 (no) | 1995-01-12 | 1997-07-03 | Fremgangsmåte for inhibering av veksthormoneffekter |
Country Status (12)
Country | Link |
---|---|
US (1) | US5494929A (no) |
EP (1) | EP0796095A4 (no) |
JP (1) | JPH10512260A (no) |
KR (1) | KR19980701329A (no) |
CN (1) | CN1177295A (no) |
AU (1) | AU701267B2 (no) |
CA (1) | CA2209891A1 (no) |
CZ (1) | CZ217497A3 (no) |
FI (1) | FI972968A0 (no) |
HU (1) | HUT77381A (no) |
NO (1) | NO973103D0 (no) |
WO (1) | WO1996021441A1 (no) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458811B1 (en) * | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
EP0910369B1 (en) * | 1996-03-26 | 2010-04-21 | Eli Lilly And Company | Benzothiophenes, formulations containing same, and methods |
GB2324726A (en) * | 1997-05-01 | 1998-11-04 | Merck & Co Inc | Combination Therapy for the Treatment of Osteoporosis |
US5990129A (en) * | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
US5445941A (en) * | 1993-06-21 | 1995-08-29 | Eli Lilly And Company | Method for screening anti-osteoporosis agents |
US5441966A (en) * | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting Turner's syndrome |
US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
-
1995
- 1995-01-12 US US08/372,753 patent/US5494929A/en not_active Expired - Fee Related
- 1995-12-22 JP JP8521682A patent/JPH10512260A/ja active Pending
- 1995-12-22 AU AU46591/96A patent/AU701267B2/en not_active Ceased
- 1995-12-22 CZ CZ972174A patent/CZ217497A3/cs unknown
- 1995-12-22 CA CA002209891A patent/CA2209891A1/en not_active Abandoned
- 1995-12-22 WO PCT/US1995/016809 patent/WO1996021441A1/en not_active Application Discontinuation
- 1995-12-22 HU HU9701873A patent/HUT77381A/hu unknown
- 1995-12-22 EP EP95943965A patent/EP0796095A4/en not_active Withdrawn
- 1995-12-22 CN CN95197739A patent/CN1177295A/zh active Pending
- 1995-12-22 KR KR1019970704718A patent/KR19980701329A/ko not_active Application Discontinuation
-
1997
- 1997-07-03 NO NO973103A patent/NO973103D0/no unknown
- 1997-07-11 FI FI972968A patent/FI972968A0/fi unknown
Also Published As
Publication number | Publication date |
---|---|
FI972968A (fi) | 1997-07-11 |
WO1996021441A1 (en) | 1996-07-18 |
HUT77381A (hu) | 1998-04-28 |
CZ217497A3 (cs) | 1998-01-14 |
JPH10512260A (ja) | 1998-11-24 |
US5494929A (en) | 1996-02-27 |
EP0796095A1 (en) | 1997-09-24 |
AU701267B2 (en) | 1999-01-21 |
MX9705215A (es) | 1997-10-31 |
NO973103D0 (no) | 1997-07-03 |
KR19980701329A (ko) | 1998-05-15 |
CN1177295A (zh) | 1998-03-25 |
AU4659196A (en) | 1996-07-31 |
CA2209891A1 (en) | 1996-07-18 |
FI972968A0 (fi) | 1997-07-11 |
EP0796095A4 (en) | 1999-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO973635L (no) | Fremgangsmåte for hemming av celle-celle adhesjon | |
DK0652005T3 (da) | Fremgangsmåder til inhibering af endometriose | |
NO944914L (no) | Fremgangsmåte for å inhibere autoimmunsykdommer | |
ZA956986B (en) | Methods of inhibiting viral replication. | |
DK0651999T3 (da) | Fremgangsmåder til inhibering af livmoderfibrose | |
MX9701325A (es) | Metodos para inhibir la mucositis ulcerativa. | |
MX9701360A (es) | Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion. | |
NO944930L (no) | Hemming av dysfunksjonell uterin blödning | |
UA32427C2 (uk) | Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань | |
NO944926L (no) | Fremgangsmåter for å inhibere myeloperoksidaseaktivitet | |
NO944924L (no) | Fremgangsmåter for inhibering av Turner's syndrom | |
NO944933L (no) | Fremgangsmåte for å inhibere sykdomstilstander i brystet | |
NO970786L (no) | Fremgangsmåte for hemming av benprotesedegradering | |
NO975580L (no) | Fremgangsmåte for å inhibere melanom | |
NO973367L (no) | Fremgangsmåte for å inhibere miljömessige östrogen | |
NO981578L (no) | FremgangsmÕte for hemming av plasminogenaktivatorhemmer I | |
NO973103L (no) | Fremgangsmåte for inhibering av veksthormoneffekter | |
NO973609L (no) | Fremgangsmåte for å inhibere effektene av IL-6 | |
NO971794L (no) | Fremgangsmåte for hemming av tilstander forbundet med bradykinin | |
NO944577L (no) | Hemming av effekten av amyloidogene proteiner | |
NO971029L (no) | Fremgangsmåter for hemming av endometriale metoser | |
NO944909L (no) | Fremgangsmåter for inhibering av mannlig infertilitet | |
MX9701333A (es) | Metodos para inhibir el daño neuronal. | |
NO944910L (no) | Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser | |
NO970783L (no) | Fremgangsmåte for å hindre endometrialkreft |